Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for TransGlobal Assets's Debt-to-EBITDA or its related term are showing as below:
TMSH's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
TransGlobal Assets Debt-to-EBITDA Related Terms
TransGlobal Assets Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for TransGlobal Assets's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransGlobal Assets Debt-to-EBITDA Chart
TransGlobal Assets Annual Data
Trend
Dec07
Dec08
Dec09
Dec10
Dec11
Debt-to-EBITDA
-0.72
-0.80
-70.00
N/A
-2.27
TransGlobal Assets Semi-Annual Data
Dec07
Dec08
Dec09
Dec10
Dec11
Debt-to-EBITDA
-0.72
-0.80
-70.00
N/A
-2.27
TMSH vs CLDOF: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TransGlobal Assets's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransGlobal Assets Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TransGlobal Assets's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TransGlobal Assets's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2011) EBITDA data.
TransGlobal Assets (TMSH) has a Debt-to-EBITDA of -2.27 as of Dec. 2011. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TransGlobal Assets.
Is TransGlobal Assets' Debt-to-EBITDA too high?
TransGlobal Assets' current Debt-to-EBITDA is -2.27.
How does TransGlobal Assets' Debt-to-EBITDA compare to CLDOF?
TransGlobal Assets' Debt-to-EBITDA of -2.27 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TransGlobal Assets. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransGlobal Assets's current Debt-to-EBITDA is -2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransGlobal Assets stock overvalued right now?
TransGlobal Assets (TMSH) has a current Debt-to-EBITDA of -2.27. The current Debt-to-EBITDA is -2.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For TransGlobal Assets (TMSH), the current Debt-to-EBITDA is -2.27 as of Dec. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransGlobal Assets Inc through its subsidiary Mindwell Solutions Group LLC (MWSG), the company develops proprietary solutions that harness AI, biometric analysis, and behavioral data to address high-growth markets, including mental health, relationship wellness, performance analytics, and sports/entertainment. and also offers a pioneer in transforming the health and wellness industries through cutting-edge products and services. The products and services are focused on being at the forefront of the health and wellness sectors, developing technologies and solutions that are driving industry growth and transforming lives. The portfolio includes a range- of-products and services, from telemedicine platforms to wellness retreats and natural health remedies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMSH has been successfully added to your 
